Prothrombin fragment 1 + 2 in urine as an indicator of sustained coagulation activation after total hip arthroplasty

Thrombosis Research

Volumn 121, Issue 3, 2007, Pages 369-376

  Borris, Lars C ^a   Breindahl, Morten ^b   Ryge, Camilla ^c   Sommer, Helle M ^d   Lassen, Michael R ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b R and D   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Danish Food and Veterinary Research   (Denmark)

Author keywords

Deep vein thrombosis; Healthy volunteers; Prothrombin fragment 1 + 2; Pulmonary embolism; Total hip arthroplasty; Urine; Vascular thrombotic complication

Indexed keywords

ARGATROBAN; DALTEPARIN; ENOXAPARIN; PROTHROMBIN; RIVAROXABAN;

ACCURACY; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; THROMBIN TIME; THROMBOSIS; TOTAL HIP PROSTHESIS; URINALYSIS; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; BIOLOGICAL MARKERS; BLOOD COAGULATION DISORDERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROTHROMBIN; THROMBOSIS;

EID: 37849031231     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.05.002     Document Type: Article

References (17)

1. Arnesen H., Dahl O.E., Aspelin T., Seljeflot I., Kierulf P., and Lyberg T. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost 1 (2003) 971-975
2. Dahl O., Aspelin T., and Arnesen H. Increased activation of coagulation and formation of late deep vein thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 80 (1995) 299-306
3. Dahl O.E., Caprini J.A., Colwell Jr. C.W., Frostick S.P., Haas S., Hull R.D., et al. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost 93 (2005) 860-866
4. Prandoni P., Bilora F., Marchiori A., Bernardi E., Petrobelli F., Lensing A., et al. An association between atherosclerosis and venous thrombosis. N Engl Med 348 (2003) 1435-1441
5. Hong C., Zhu F., Du D., Pilgram T.K., Sicard G.A., and Bae K.T. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 183 (2005) 169-174
6. Bezeaud A., Aronson D.L., Menache D., and Gullin M.C. Identification of a prothrombin derivative in human urine. Thromb Res 13 (1978) 551-556
7. Sorensen J.V., Jensen H.P., Rahr H.B., Borris L.C., Lassen M.R., and Knudsen F. F1 + 2 and FpA in urine from patients with multiple trauma and healthy individuals. A pilot study. Thromb Res 67 (1992) 429-434
8. Lind S.E., Goldshteyn S., Barry C.P., Lindquist J.R., Piergies A.A., Rosen T., et al. Assessment of coagulation system activation using spot urine measurements. Blood Coagul Fibrinolysis 10 (1999) 285-289
9. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., et al. Prevention of venous thromboembolism. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 338S-400S
10. Eikelboom J.W., Quinlan D.J., and Douketis J.D. Extended-duration prophylaxis against venousthromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358 (2001) 9-15
11. Salvati E.A., Pellegrini V.D., Sharrock N.E., Lotke P.A., Murray D.W., Potter H., et al. Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg 82-A (2000) 252-270
12. Barnes R.W., Nix M.L., Barnes C.L., Lavender R.C., Golden W.E., Harmon B.H., et al. Perioperative asymptomatic venous thrombosis: role of duplex scanning versus venography. J Vasc Surg 9 (1989) 251-260
13. Chumas P., O'Doherty D.P., Pearse M., Magnussen P., Crozier A., and Gregg P.J. Preoperative lower limb venography in patients undergoing total hip arthroplasty. J Arthroplast 3 (1988) 225-228
14. Sørensen J.V., Lassen M.R., Borris L.C., et al. Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparin. Blood Coagul Fibrinolysis 3 (1992) 55-59
15. Planes A., Vochelle N., Darman J.-Y., Fagola M., Bellaud M., and Huet Y. Risk of deep-vein thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 348 (1996) 224-228
16. Dahl O.E., Andreassen G., Aspelin T., Müller C., Mathiesen P., Nyhus S., et al. Prolonged thromboprophylaxis following hip replacement surgery results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 77 (1997) 26-31
17. Bergqvist D., and Jonsson B. Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health 2 (1999) 288-294